Ok, the Bioshares Summit presentation has shed more light on...

Ok, the Bioshares Summit presentation has shed more light on this.

Slide 12 of the presentation shows 6 potential indications in clinic in 2025.

The indications of RP11 and ADOA will potentially have 4 trials each – SAD, MAD, Pivotal and an ongoing Natural History Study.

ADPKD and PMS should both have advanced into SAD trials.

Once Phase 1 safety in ADOA has been successfully cleared, the intention is to progress PYC-001 into further indications (with the help of partners?)

Rohan Hockings has previously suggested that there are other bioenergetic diseases of retinal ganglion cells which could potentially be addressed by PYC-001. Two examples of other potential indications for VP-001, provided in Slide 12, are glaucoma and Leber hereditary optic neuropathy (LHON).

Glaucoma is obviously a highly prevalent indication and PYC has filed a patent application for Methods of Treating Glaucoma.

LHON has an addressable population similar to ADOA. One key difference though is that vision decline in LHON occurs very rapidly, over 6 -12 months. Therefore, treatment effect would likely be measurable in a much shorter space of time.